Back to Results

Aclarion Inc (ACON)

Aclarion Inc. is a healthcare technology company based in Broomfield, Colorado, and its common stock trades on NASDAQ under the ticker ACON. The company develops products that use magnetic resonance spectroscopy (MRS) and proprietary biomarkers to support clinical decision-making in spine care. Its NOCISCAN platform is designed to non-invasively assess the chemical composition of intervertebral discs, while the NOCISCAN MRS Exam Protocol is a custom software workflow for use with commercially available MRS pulse sequences during lumbar MRI procedures. Aclarion also provides imaging data transfer capabilities through AMBRA Healthcare. In addition, the NOCISCAN Post-Processor Suite includes NOCICALC, which processes raw exam data into spectra and biomarker calculations, and NOCIGRAM, which converts those results into NOCISCORES on a 0-10 scale.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NASDAQ-ACON
$3.33
31.1% Upside
Undervalued
$7.50
195.3% Upside
Bargain
Weak
—
—
—
0.0%
August 28, 2026
-0.8x
0.3x
80.6x
6.476 M
-12.736 M
0.0%
89.4%
17.1
—
90.9%
Send a message
Valuation • Fair Value

Aclarion Inc (NASDAQ-ACON) Fair Value by Valuation Model

Compare the primary fair value estimate for Aclarion Inc (NASDAQ-ACON) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$3.33

Estimated upside of 31.1% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

NM

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

$3.33

Comparable-company valuation reference.

Analyst Price Target

$7.50

Analysts imply upside of 195.3%.

How to read these valuation models

Use this section to compare the primary fair value estimate for Aclarion Inc (NASDAQ-ACON) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Aclarion Inc (NASDAQ-ACON)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

77.879 K

Current operating scale indicator.

Revenue Forecast

135 K

Forward revenue estimate.

EBITDA

-8.314 M

Current operating profitability reference.

EBITDA Forecast

Not available

Data is currently unavailable.

How to read profitability and growth

This section helps investors review Aclarion Inc (NASDAQ-ACON) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Aclarion Inc (NASDAQ-ACON)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

4

Mid-range quality score.

Beneish M-Score

-4.20

No elevated caution signal from this screen.

Altman Z-Score

17.1

Relatively strong balance-sheet zone.

FCF / Net Income

90.9%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Aclarion Inc (NASDAQ-ACON). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Aclarion Inc (NASDAQ-ACON)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

August 28, 2026

Days to Earnings

38

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Aclarion Inc (NASDAQ-ACON), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Aclarion Inc (NASDAQ-ACON) Stock Forecast & Technical Outlook

Review Aclarion Inc (NASDAQ-ACON) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Aclarion Inc (NASDAQ-ACON) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Aclarion Inc (NASDAQ-ACON) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Aclarion Inc (NASDAQ-ACON) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Aclarion Inc (NASDAQ-ACON) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Aclarion Inc (NASDAQ-ACON) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Aclarion Inc (NASDAQ-ACON)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Aclarion Inc (NASDAQ-ACON) has a Strong Buy consensus, with 1 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 1
Hold 0
Sell 0
FAQ • Fast Investor Answers

Aclarion Inc (NASDAQ-ACON) Stock FAQ

Quick answers about Aclarion Inc (NASDAQ-ACON) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$3.33
Estimated upside 31.1%
Valuation Rating
Undervalued
Estimated upside of 31.1%
Analyst Target
$7.50
Implied upside 195.3%
Financial Health
Weak
Current financial-health read

The current fair value estimate for Aclarion Inc (NASDAQ-ACON) is $3.33. This implies an estimated upside of 31.1% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 31.1% versus the current market price.

The available analyst price target for Aclarion Inc (NASDAQ-ACON) is $7.50. The analyst target implies estimated upside of 195.3%.

The current financial health read for Aclarion Inc (NASDAQ-ACON) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Aclarion Inc (NASDAQ-ACON) is August 28, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for Aclarion Inc (NASDAQ-ACON) is -0.8x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Aclarion Inc is 6.476 M.

The current enterprise value listed for Aclarion Inc is -12.736 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Aclarion Inc is NASDAQ-ACON, and the stock is listed on NASDAQ.

Aclarion Inc (NASDAQ-ACON) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Aclarion Inc is 0.0%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Aclarion Inc is 89.4%. Free float helps investors understand how much of the share base is available for public trading.

Similar Health Care Technology Stocks on NASDAQ View more

Waystar Holding Corp (WAY) Waystar Holding Corp (WAY)
Heartflow Inc (HTFL) Heartflow Inc (HTFL)
Schrodinger Inc (SDGR) Schrodinger Inc (SDGR)
Certara Inc (CERT) Certara Inc (CERT)
Goodrx Holdings Inc (GDRX) Goodrx Holdings Inc (GDRX)
HealthStream Inc (HSTM) HealthStream Inc (HSTM)
Sophia Genetics SA (SOPH) Sophia Genetics SA (SOPH)
Trubridge Inc (TBRG) Trubridge Inc (TBRG)
Simulations Plus Inc (SLP) Simulations Plus Inc (SLP)
LifeMD Inc (LFMD) LifeMD Inc (LFMD)
LifeMD Inc Preferred Series A (LFMDP) LifeMD Inc Preferred Series A (LFMDP)
Health Catalyst Inc (HCAT) Health Catalyst Inc (HCAT)
OPTIMIZERx Corp (OPRX) OPTIMIZERx Corp (OPRX)
Definitive Healthcare Corp (DH) Definitive Healthcare Corp (DH)
CareCloud Inc (CCLD) CareCloud Inc (CCLD)
DarioHealth Corp (DRIO) DarioHealth Corp (DRIO)
Onemednet Corp (ONMD) Onemednet Corp (ONMD)
ITonic Holdings Ltd (ITOC) ITonic Holdings Ltd (ITOC)
Firefly Neuroscience Inc (AIFF) Firefly Neuroscience Inc (AIFF)
Scienture Holdings Inc (SCNX) Scienture Holdings Inc (SCNX)
BullFrog AI Holdings Inc Unit (BFRG) BullFrog AI Holdings Inc Unit (BFRG)
Vsee Health Inc (VSEE) Vsee Health Inc (VSEE)
Healthcare Triangle Inc (HCTI) Healthcare Triangle Inc (HCTI)
ISpecimen Inc (ISPC) ISpecimen Inc (ISPC)